Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis

Journal of Neural Transmission

Volumn 104, Issue 11-12, 1997, Pages 1305-1311

  Rudolf, J ^a   Grond, M ^a   Neveling, M ^a   Heiss, W D ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Agranulocytosis; Clozapine; Dopaminergic psychosis; Granulocyte colony stimulating factor; Neutropenia; Parkinson's disease

Indexed keywords

CLOZAPINE; GRANULOCYTE COLONY STIMULATING FACTOR; NEUROLEPTIC AGENT;

AGED; AGRANULOCYTOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CASE REPORT; DOPAMINERGIC SYSTEM; HUMAN; MALE; NEUTROPENIA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; THROMBOCYTOPENIA;

AGED; AGRANULOCYTOSIS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE AGENTS; HUMANS; LEUKOCYTE COUNT; MALE; PARKINSON DISEASE; PLATELET COUNT; PSYCHOSES, SUBSTANCE-INDUCED; THROMBOCYTOPENIA;

EID: 0031435387     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01294731     Document Type: Article

References (23)

1. Alvir JM, Lieherman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329: 162-167
2. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169: 483-488
3. Durst R, Dorevitch A, Fraenkel Y (1993) Platelet dysfuction associated with clozapine therapy. South Med J 86: 1170-1172
4. Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 7: 125-131
5. Factor SA, Sanchez-Ramos JR, Weiner WJ (1988) Parkinson's disease: an open trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 51: 529-533
6. Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 44: 544-546
7. Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson's disease: drug-induced psychiatric states. Adv Neurol 65: 115-138
8. Gallin JI (1988) Disorders of phagocytic cells. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds) Harrison's principles of internal medicine, 11th edn. McGraw Hill, New York, pp 279-283
9. Gerson SL (1994) G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 55 [Suppl B]: 1389-142
10. Goodwin FK (1971) Psychiatric side effects of levodopa in man. JAMA 218: 1915-1929
11. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
12. Klimke A, Klieser E (1995) Das atypische Neuroleptikum Clozapin (Leponex®) - aktueller Kenntnisstand und neuere klinische Aspekte. Fortschr Neurol Psychiatr 63: 173-193
13. Lieberman JA, Alvir JM (1992) A report on clozapine induced agranulocytosis in the United States. Drug Safety 7 [Suppl 1]: 1-2
14. Marsden CD, Fahn S (1981) Problems in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 1-7
15. Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3: 64-75
16. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 12: 39-45
17. Pfeiffer C, Wagner ML (1994) Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 51: 3047-3053
18. Pinter MM, Helscher RJ (1993) Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm [PD Sect] 5: 135-146
19. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA (1992) On the possible mechanisms and predictability of clozapine induced agranulocytosis. Drug Safety 7 [Suppl 1]: 33-44
20. Rebey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD (1995) Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 45: 432-434
21. Rondot R, deRecondo J, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 40: 259-269
22. Veys PA, Wilkes S, Shah SA, Noyelle R, Hoffbrand AV (1992) Clinical experience of clozapine-induced neutropenia in the UK: laboratory investigation using liquid culture systems and immunofluorocytometry. Durg Safety 7 [Suppl 1]: 26-32
23. Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treat 5: 257-282